Utilizing genetics and proteomics to assess the role of antihypertensive drugs in human longevity and the underlying pathways: a Mendelian randomization study
Authors' conclusion
Beta-blockers, CCBs, and vasodilators may prolong lifespan, with potential sex differences for BBs and CCBs. The role of CCBs in lifespan is partly mediated by CDH1.
Study context
- Population
- European participants of UK Biobank and LifeGen (lifespan GWAS)
- Participants
- 1 million GWAS participants
- Comparison
- Genetically proxied antihypertensive drug classes and lifespan
- Outcome
- Lifespan (life years)
Methodological detailsdrug-target MR, proteomic mediation analysis, sex-specific analysis, colocalization
- Drug-target MR
- Proteomic mediation analysis
- Sex-specific analysis
- Colocalization
Main finding
As reported in the abstract
Life years per 5 mmHg SBP reduction
Further findings
Sex-specific analysis
- Beneficial effects of beta-blockers (BBs) and calcium channel blockers (CCBs) more obvious in men
Drug-target genes
- ADRB1, CACNA2D2, CACNB3, CPT1A, CPT2 and EDNRA related to extended lifespan; CPT2 supported by colocalization
Plasma proteins (2291 assessed)
- Proteins related to lifespan
- 86
- Lifespan-related proteins affected by CCBs
- 4
- CDH1 may mediate CCB–lifespan association
Original publication
Utilizing genetics and proteomics to assess the role of antihypertensive drugs in human longevity and the underlying pathways: a Mendelian randomization study. Eur Heart J Cardiovasc Pharmacother. Published 20 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →